secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001157523-22-001506
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q3 net loss $17.5M ($0.34/shr); cash $365M; EDG-5506 shows biomarker reductions
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $365M as of Sept 30, 2022; underwritten offering raised $129M net.
- Net loss $17.5M ($0.34 per share) vs $16.1M ($0.32) prior quarter; R&D spend $13.9M.
- Positive 6-month ARCH interim data: CK reduced 39%, fast skeletal troponin I reduced 75% in BMD adults.
- CANYON Phase 2 trial in BMD (n≈66) and LYNX Phase 2 trial in DMD (n≈27) both advancing; no approved treatments.
- EDG-002 preclinical program targets hypertrophic cardiomyopathy; IND-enabling studies planned for 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/0001157523-22-001506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000115752322001506/a52959492.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer